BioStock: Immunicum can look back on a transformative 2021

Following the merger with DCprime in late 2020, Swedish cancer immunotherapy company Immunicum has built an advanced clinical pipeline addressing two major challenges in oncology: hard-to-treat solid tumours and tumour recurrence. BioStock reached out to Immunicum’s CEO Erik Manting to get his thoughts on the company’s achievements during 2021 and what to expect from Immunicum in 2022.

Read the interview with Immunicum's CEO Erik Manting at biostock.se:

https://www.biostock.se/en/2022/01/immunicum-can-look-back-on-a-transformative-2021/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se